USPTO aims to fend off Fintiv challenge at SCOTUS

Controversial rule precludes a patent review if there is parallel litigation | Big pharma and tech companies insist the rule is “arbitrary and capricious” | US agency backs Vidal’s authority, calling a proposed intervention “unnecessary”.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

2024 forecast: AI, patent eligibility and Fintiv

2 January 2024 Life science attorneys should see some notable developments relating to artificial intelligence, patent eligibility and the Fintiv rule, write Manita Rawat and Alexander Stein of Morgan Lewis.

Americas

Edwards Lifesciences revives Fintiv challenge

14 March 2023 Medtech company wins reversal of earlier ruling | Door opens to mount a challenge of controversial rule | USPTO director‘s updated guidelines influence court’s reasoning.

Americas

Mylan, Edwards back NHK-Fintiv challenge

31 August 2021 Mylan Pharmaceutical and Edwards Lifesciences have joined a petition urging the US Supreme Court to order the US Court of Appeals for the Federal Circuit to reconsider inter partes review petitions that have been denied due to the NHK-Fintiv rule.

More on this story

Americas

Edwards Lifesciences revives Fintiv challenge

14 March 2023 Medtech company wins reversal of earlier ruling | Door opens to mount a challenge of controversial rule | USPTO director‘s updated guidelines influence court’s reasoning.

Americas

Mylan, Edwards back NHK-Fintiv challenge

Big Pharma

2024 forecast: AI, patent eligibility and Fintiv

More on this story

Americas

Edwards Lifesciences revives Fintiv challenge

14 March 2023 Medtech company wins reversal of earlier ruling | Door opens to mount a challenge of controversial rule | USPTO director‘s updated guidelines influence court’s reasoning.

Americas

Mylan, Edwards back NHK-Fintiv challenge

Big Pharma

2024 forecast: AI, patent eligibility and Fintiv